Cefpodoxime

Structural formula
General
Non-proprietary name	Cefpodoxime
other names	(6 R , 7 R ) -7 - {[(2 Z ) -2- (2-amino-1,3-thiazol-4-yl) -2-methoxyimino-acetyl] amino} -3- (methoxymethyl) - 8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylic acid
Molecular formula	C 15 H 17 N 5 O 6 S 2
External identifiers / databases
EC number	685-334-0
ECHA InfoCard	100.210.871
PubChem	6335986
ChemSpider	4891496
DrugBank	DB01416
Wikidata	Q415173
Drug information
ATC code	J01 DD13
Drug class	β-lactam antibiotics; (3rd generation cephalosporins)
properties
Molar mass	427.458 g · mol -1
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS hazard labeling ; no classification available
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Cefpodoxime is an antibiotic from the group of third generation cephalosporins and is administered orally (oral cephalosporin).

application

Cefpodoxime is used to treat infections

the sinuses ,
of the throat and tonsillitis ,
the respiratory tract: acute bronchitis and pneumonia ,
the urinary tract (uncomplicated), inflammation of the bladder and kidney pelvis ,
the skin and soft tissues ,
the urethra in uncomplicated gonorrhea .

It is also used as oral continuation therapy when intravenous cephalosporins are no longer necessary for sustained treatment. The antibiotic is also used in veterinary medicine.

It is recommended by the Paul Ehrlich Society as the drug of choice for the treatment of acute otitis media , acute sinusitis and the exacerbation of chronic bronchitis .

Spectrum of activity

Cefpodoxime is active against most gram-positive and gram-negative organisms.

Staphylococcus aureus ( methicillin- sensitive) is moderately to well sensitive . Other sensitive germs are Streptococcus pneumoniae , B-streptococci ( Streptococcus agalactiae ), Streptococcus pyogenes , Haemophilus influenzae , Moraxella catarrhalis , Escherichia coli , Klebsiella pneumoniae , Proteus mirabilis and other enterobacteria .

Pseudomonas aeruginosa , enterococci , Bacteroides fragilis and Proteus vulgaris , for example, are naturally resistant . Some germs can be insensitive to cefpodoxime due to an acquired antibiotic resistance, e.g. Morganella morganii , Citrobacter spp. and Enterobacter spp.

application

Cefpodoxime is administered orally as a prodrug variant of cefpodoxime proxetil .

Individual evidence

↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
↑ H. Scholz, F. Vogel, Marianne Abele-Horn, D. Adam and others: Rational use of oral antibiotics in children and adolescents. Recommendations of an expert commission of the Paul Ehrlich Society for Chemotherapy e. V. In: Chemotherapy Journal. 11, 2002, pp. 59-70.
↑ F. Vogel, H. Scholz, B. Al-Nawas, W. Elies and others: Rational use of oral antibiotics in adults. Recommendations of an expert commission of the Paul Ehrlich Society for Chemotherapy e. V. In: Chemotherapy Journal. 11, 2002, pp. 47-58.
^ H. Scholz, KG Naber and the expert group of the Paul Ehrlich Society for Chemotherapy eV, Chemietherapie Journal 8, 1999, pp. 227–229 (PDF) ( Memento from September 20, 2009 in the Internet Archive ).
↑ ^a ^b Recommendations of an expert commission of the Paul Ehrlich Society for Chemotherapy e. V., Chemotherapy Journal 15, 2006, pp. 129-145 (PDF) ( Memento from September 20, 2009 in the Internet Archive ).
↑ Cefpodoxime Proxetil - a new cephalosporin for oral use. In: Journal for Infection Therapy. 1992, accessed February 16, 2016 .
↑ Product information Cefpodoxime Sandoz 100 mg film-coated tablets / 200 mg film-coated tablets / 40 mg / 5 ml powder for oral suspension. As of December 2007.

[NV-1] This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.

[2] H. Scholz, F. Vogel, Marianne Abele-Horn, D. Adam and others: Rational use of oral antibiotics in children and adolescents. Recommendations of an expert commission of the Paul Ehrlich Society for Chemotherapy e. V. In: Chemotherapy Journal. 11, 2002, pp. 59-70.

[3] F. Vogel, H. Scholz, B. Al-Nawas, W. Elies and others: Rational use of oral antibiotics in adults. Recommendations of an expert commission of the Paul Ehrlich Society for Chemotherapy e. V. In: Chemotherapy Journal. 11, 2002, pp. 47-58.

[4] H. Scholz, KG Naber and the expert group of the Paul Ehrlich Society for Chemotherapy eV, Chemietherapie Journal 8, 1999, pp. 227–229 (PDF) ( Memento from September 20, 2009 in the Internet Archive ).

[CJ2006-5] Recommendations of an expert commission of the Paul Ehrlich Society for Chemotherapy e. V., Chemotherapy Journal 15, 2006, pp. 129-145 (PDF) ( Memento from September 20, 2009 in the Internet Archive ).

[6] Cefpodoxime Proxetil - a new cephalosporin for oral use. In: Journal for Infection Therapy. 1992, accessed February 16, 2016 .

[7] Product information Cefpodoxime Sandoz 100 mg film-coated tablets / 200 mg film-coated tablets / 40 mg / 5 ml powder for oral suspension. As of December 2007.